Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ITOC 2020 | HDACi and IL21: reprogramming CD8+ T-cells to memory T-cells

Cassian Yee, MD, MD Anderson Cancer Center, The University of Texas, Houston, TX, discusses the in vitro generation of highly persistent T-cell populations using histone deacetylase inhibitor (HDACi) and IL21 to reprogram differentiated human CD8+ T-cells into central memory–like T-cells. This can augment the efficacy of adoptively transferred T-cells as there is a correlation with clinical response rates in adoptive cell therapy (ACT). This interview took place during the 7th Immunotherapy of Cancer Conference (ITOC) 2020.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.